Botulinum Toxin for Hyperhidrosis in Palmoplantar Area

  • Eloisa Leis AyresEmail author
  • Maria Claudia Almeida Issa
Living reference work entry

Latest version View entry history

Part of the Clinical Approaches and Procedures in Cosmetic Dermatology book series (CAPCD)


Hyperhidrosis is a skin condition that leads to excessive production of sweat more than required for normal thermoregulation, affecting both men and women from childhood or adolescence. It is estimated that hyperhidrosis affects 3% of the US population. Areas such as the palms and soles are frequently affected, and it may exert deep negative impact on patient’s personal and professional life. Treatment is difficult, and various therapeutic methods are available with limited effectiveness. Botulinum toxin has been used for 20 years safely and effectively. We will discuss the literature and bring clinical experience with this treatment.


Sweat Hyperhidrosis Botulinum toxin 


  1. Almeida AR, Kadunc BV, de Oliveira EM. Improving botulinum toxin therapy for palmar hyperhidrosis: wrist block and technical considerations. Dermatol Surg. 2001;27(1):34–6.PubMedCrossRefGoogle Scholar
  2. Ayres EL. Up date no tratamento clínico das hiperidroses. In: Kede e Sabatovitch. Dermatologia Estética. 3rd ed. Rio de Janeiro: Atheneu; 2015.Google Scholar
  3. Ayres EL, Sandoval MHL. Toxina Botulínica na Dermatologia. 1st ed. Rio de Janeiro: Guanabara Koogan; 2016.Google Scholar
  4. Benohanian A. What stands in the way of treating palmar hyperhidrosis as effectively as axillary hyperhidrosis with botulinum toxin type A. Dermatol Online J. 2009;15(4):12.PubMedGoogle Scholar
  5. Brown AL, Gordon J, Hill S. Hyperhidrosis: review of recent advances and new therapeutic options for primary hyperhidrosis. Curr Opin Pediatr. 2014;26(4):460–5.PubMedCrossRefGoogle Scholar
  6. Campanati A, Penna L, Guzzo T, Menotta L, Silvestri B, Lagalla G, Gesuita R, Offidani A. Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study. Clin Ther. 2003;25(1):298–308.PubMedCrossRefGoogle Scholar
  7. Chia HY, Tan AS, Chong WS, Tey HL. Efficacy of iontophoresis with glycopyrronium bromide for treatment of primary palmar hyperhidrosis. J Eur Acad Dermatol Venereol. 2012;26(9):1167–70.PubMedCrossRefGoogle Scholar
  8. Davarian S, Kalantari KK, Rezasoltani A, Rahimi A. Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis. Aust J Dermatol. 2008;49(2):75–9.CrossRefGoogle Scholar
  9. D’Epiro S, Macaluso L, Salvi M, Luci C, Mattozzi C, Marzocca F, Salvo V, Scarnò M, Calvieri S, Richetta A. Safety and prolonged efficacy of Botulinum Toxin A in a primary hyperhidrosis. Clin Ter. 2014;165(6): e395–400.Google Scholar
  10. Doft MA, Hardy KL, Ascherman JA. Treatment of hyperhidrosis with botulinum toxin. Aesthet Surg J. 2012;32(2):238–44.PubMedCrossRefGoogle Scholar
  11. El Kahky HM, Diab HM, Aly DG, Farag NM. Efficacy of onabotulinum toxin A (Botox) versus abobotulinum toxin A (Dysport) using a conversion factor (1 : 2.5) in treatment of primary palmar hyperhidrosis. Dermatol Res Pract. 2013;2013:686329.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Gordon JR, Hill SE. Update on pediatric hyperhidrosis. Dermatol Ther. 2013;26(6):452–61.PubMedCrossRefGoogle Scholar
  13. Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis a review. Am J Clin Dermatol. 2009;10(2):87–102.PubMedCrossRefGoogle Scholar
  14. Haak CS, Bhayana B, Farinelli WA, Rox Anderson R, Haedersdal M. The impact of treatment density and molecular weight for fractional laser-assisted drug delivery. J Control Release. 2012;163:335–41.PubMedCrossRefGoogle Scholar
  15. International Hyperidrosis Society. Accessed May 2016
  16. Issa MCA, Kassuga LEB, Chevrand NS, Barbosa LN, Luiz RR, Pantaleão L, Vilar EG, Rochael MC. Transepidermal retinoic acid delivery using ablative fractional radiofrequency associated with acoustic pressure ultrasound for stretch marks treatment. Lasers Surg Med; 2012. [Epub ahead of print].Google Scholar
  17. Issa MCA, Kassuga LEBP, Chevrand NS, Pires MTF. Topical delivery of triamcinolone via skin pretreated with ablative radiofrequency: a new method in hypertrophic scar treatment. Int J Dermatol. 2013;52:367–70.PubMedCrossRefGoogle Scholar
  18. Issa MCA, Pires M, Silveira P, et al. Transepidermal drug delivery: a new treatment option for areata alopecia. J Cosmet Laser Ther. 2015;17:37–40.PubMedCrossRefGoogle Scholar
  19. Kacar SD, Ozuguz P, Eroglu S, Polat S, Karaca S. Treatment of primary hyperhidrosis with tap water iontophoresis in paediatric patients: a retrospective analysis. Cutan Ocul Toxicol. 2014;33(4):313–6.CrossRefGoogle Scholar
  20. Kouris A, Armyra K, Stefanaki C, Christodoulou C, Karimali P, Kontochristopoulos G. Quality of life and social isolation in Greek adolescents with primary focal hyperhidrosis treated with botulinum toxin type A: a case series. Pediatr Dermatol. 2015;32(2):226–30.PubMedCrossRefGoogle Scholar
  21. Kumar MG, Foreman RS, Berk DR, Bayliss SJ. Oral glycopyrrolate for refractory pediatric and adolescent hyperhidrosis. Pediatr Dermatol. 2014;31(1):e28–30.PubMedCrossRefGoogle Scholar
  22. Letada PR, Shumaker PR, Uebelhoer NS. Demonstration of protoporphyrin IX (PpIX) localized to areas of palmar skin injected with 5-aminolevulinic acid (ALA) and pre-treated with a fractionated CO2 laser prior to topically applied ALA. Photodiagn Photodyn Ther. 2010;7(2):120–2.CrossRefGoogle Scholar
  23. Paller AS, Shah PR, Silverio AM, Wagner A, Chamlin SL, Mancini AJ. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. J Am Acad Dermatol. 2012;67(5):918–23.PubMedCrossRefGoogle Scholar
  24. Santos LHC, Gomes AM, Giraldi S, Abagge KT, Marinoni LP. Palmar hyperhidrosis: long-term follow-up of nine children and adolescents treated with botulinum toxin type A. Pediatr Dermatol. 2009;26(4):439–44.CrossRefGoogle Scholar
  25. Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, Smith KC, Storwick G. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908–23.PubMedPubMedCentralGoogle Scholar
  26. Tamura BM, Cucé LC, Souza RL, Levites J. Plantar hyperhidrosis and pitted keratolysis treated with botulinum toxin injection. Dermatol Surg. 2004;30(12 Pt 2):1510–4.PubMedGoogle Scholar
  27. Thorlacius L, Gyldenløve M, Zachariae C, Carlsen BC. Distinguishing hyperhidrosis and normal physiological sweat production: new data and review of hyperhidrosis data for 1980-2013. Int J Dermatol. 2015;54:e409–15.PubMedCrossRefGoogle Scholar
  28. Wolosker N, Schvartsman C, Krutman M, Campbell TP, Kauffman P, de Campos JR, Puech-Leão P. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old. Pediatric Dermatol. 2014;31(1):48–53.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Eloisa Leis Ayres
    • 1
    • 2
    Email author
  • Maria Claudia Almeida Issa
    • 3
  1. 1.Department of Clinical MedicineFluminense Federal UniversityNiteroiBrazil
  2. 2.Universidade Federal FluminenseNiteróiBrazil
  3. 3.Department of Clinical Medicine (Dermatology)Fluminense Federal UniversityNiteróiBrazil

Personalised recommendations